IL180078A - Derivatives of 9-cis retinal for use in treating deficiency of 11-cis retinal - Google Patents

Derivatives of 9-cis retinal for use in treating deficiency of 11-cis retinal

Info

Publication number
IL180078A
IL180078A IL180078A IL18007806A IL180078A IL 180078 A IL180078 A IL 180078A IL 180078 A IL180078 A IL 180078A IL 18007806 A IL18007806 A IL 18007806A IL 180078 A IL180078 A IL 180078A
Authority
IL
Israel
Prior art keywords
cis
retinal
treatment
deficiency
derivative
Prior art date
Application number
IL180078A
Other languages
English (en)
Hebrew (he)
Other versions
IL180078A0 (en
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of IL180078A0 publication Critical patent/IL180078A0/en
Publication of IL180078A publication Critical patent/IL180078A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
    • C07C403/10—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by etherified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
    • C07C403/12—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/14—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/20—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL180078A 2004-06-18 2006-12-14 Derivatives of 9-cis retinal for use in treating deficiency of 11-cis retinal IL180078A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58088904P 2004-06-18 2004-06-18
PCT/US2005/021812 WO2006002097A2 (en) 2004-06-18 2005-06-20 Retinal derivatives and methods for the use thereof for the treatment of visual disorders

Publications (2)

Publication Number Publication Date
IL180078A0 IL180078A0 (en) 2007-05-15
IL180078A true IL180078A (en) 2014-01-30

Family

ID=35782277

Family Applications (4)

Application Number Title Priority Date Filing Date
IL180078A IL180078A (en) 2004-06-18 2006-12-14 Derivatives of 9-cis retinal for use in treating deficiency of 11-cis retinal
IL222347A IL222347A (en) 2004-06-18 2012-10-11 11-cis retinyl ester for use in the treatment of 11-cis and androgenic retinyl
IL230241A IL230241A (en) 2004-06-18 2013-12-30 Retinal history and methods of using them to treat visual irregularities
IL230242A IL230242A (en) 2004-06-18 2013-12-30 Retinal history and methods of using them to treat visual irregularities

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL222347A IL222347A (en) 2004-06-18 2012-10-11 11-cis retinyl ester for use in the treatment of 11-cis and androgenic retinyl
IL230241A IL230241A (en) 2004-06-18 2013-12-30 Retinal history and methods of using them to treat visual irregularities
IL230242A IL230242A (en) 2004-06-18 2013-12-30 Retinal history and methods of using them to treat visual irregularities

Country Status (26)

Country Link
US (8) US7951841B2 (2)
EP (5) EP2397131B1 (2)
JP (2) JP5166026B2 (2)
KR (4) KR20140140616A (2)
CN (2) CN1988898B (2)
AU (1) AU2005257997B2 (2)
BR (1) BRPI0511396B1 (2)
CA (2) CA2571049C (2)
CY (2) CY1114873T1 (2)
DK (2) DK2397133T3 (2)
ES (4) ES2644984T3 (2)
HR (1) HRP20140116T1 (2)
HU (1) HUE036596T2 (2)
IL (4) IL180078A (2)
IN (1) IN2012DN09335A (2)
LT (1) LT2397133T (2)
MX (2) MXPA06014750A (2)
NO (1) NO339969B1 (2)
NZ (2) NZ587006A (2)
PL (2) PL1765322T3 (2)
PT (2) PT2397133T (2)
RS (1) RS53178B (2)
RU (2) RU2554003C2 (2)
SI (2) SI2397133T1 (2)
WO (1) WO2006002097A2 (2)
ZA (1) ZA200700368B (2)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3326623A1 (en) 2003-03-14 2018-05-30 University of Washington Retinoid replacements and opsin agonists and methods for the use thereof
NZ587006A (en) 2004-06-18 2011-12-22 Univ Washington 11-cis-Retinal derivatives and methods for the use thereof for the treatment of visual disorders
PL1768657T3 (pl) 2004-06-23 2009-01-30 Revision Therapeutics Inc Sposoby i kompozycje do leczenia stanów ocznych za pomocą pochodnych retinylowych
CA2584845C (en) * 2004-12-08 2009-02-17 Sirion Therapeutics, Inc. Methods, assays and compositions for treating retinol-related diseases
WO2008013984A2 (en) * 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Compositions and methods for treating or preventing ophthalmic disease
AU2007277032A1 (en) * 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Opsin stabilizing compounds and methods of use
WO2008063768A2 (en) * 2006-10-12 2008-05-29 Case Western Reserve University Compositions and methods for treating metabolic diseases
CA2681850C (en) * 2007-04-20 2013-07-23 Acucela Inc. Styrenyl derivative compounds for treating ophthalmic diseases and disorders
AU2015200520B2 (en) * 2008-02-11 2017-02-09 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction
WO2009102418A1 (en) * 2008-02-11 2009-08-20 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction
WO2009133552A2 (en) 2008-04-29 2009-11-05 Nikken Sohonsha Corporation Methods of treating ophthalmic disorders
IN2012DN00352A (2) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
CN102612375B (zh) * 2009-09-15 2016-01-27 Qlt股份有限公司 含有在脂质媒介物中的9-顺式-视黄酯的药物制剂
ES2758554T3 (es) 2009-12-08 2020-05-05 Univ Case Western Reserve Aminoácidos gama para tratamiento de trastornos oculares
US8889660B2 (en) 2010-01-20 2014-11-18 Case Western Reserve University Methods for treating obesity or an obesity related condition
CN107308143A (zh) * 2010-04-19 2017-11-03 诺维利昂治疗股份有限公司 用于治疗或改善与内源性类视黄醇缺乏有关的视觉障碍的治疗方案和方法
CA2816968C (en) * 2010-11-05 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Optically-controlled cns dysfunction
US10226536B2 (en) 2011-11-28 2019-03-12 Case Western Reserve University Polysaccharide therapeutic conjugates
JP6576636B2 (ja) * 2012-03-01 2019-09-18 ノベリオン セラピューティクス インコーポレイテッド 内因性レチノイド欠乏に関連する視覚障害における視覚機能を改善するための治療的計画および方法
US20150038582A1 (en) * 2012-03-01 2015-02-05 Qlt Inc. Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
WO2013185055A1 (en) 2012-06-07 2013-12-12 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of pin1
WO2013188727A2 (en) * 2012-06-15 2013-12-19 The Children's Hospital Of Philadelphia Novel pro- and codrug derivatives for nanoparticle delivery of select anticancer agents formed using rapidly cleavable phenolic ester bridges
US10471118B2 (en) 2014-05-30 2019-11-12 Case Western Reserve University Retinylamine derivitives for treatment of ocular disorders
US11129845B2 (en) 2014-06-18 2021-09-28 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
WO2016011265A2 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Biomarkers for pin1-associated disorders
US10925980B2 (en) 2014-08-04 2021-02-23 Case Western Reserve University Molecular probes and methods of use
US10548864B2 (en) 2015-03-12 2020-02-04 Beth Israel Deaconess Medical Center, Inc. Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
US11407786B2 (en) 2015-06-18 2022-08-09 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
US12060318B2 (en) 2015-10-09 2024-08-13 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
KR20190020661A (ko) * 2016-04-28 2019-03-04 스파크 테라퓨틱스, 인코포레이티드 아이소메로하이드롤라아제를 인코딩하는 바이러스 벡터에 대한 상대 효능 검정
CN116056691A (zh) * 2020-06-09 2023-05-02 典晶生物医药科技(苏州)有限公司 使用每日低剂量的类视黄醇化合物治疗视觉障碍的方法
WO2023150258A1 (en) * 2022-02-04 2023-08-10 New York University Use of retinoids for treatment of atrial fibrillation

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB797977A (en) * 1956-01-16 1958-07-09 Hoffmann La Roche Vitamin-a esters and a process for the manufacture thereof
US3196048A (en) 1961-12-19 1965-07-20 Exxon Research Engineering Co Cathode catalyst for fuel cells
US3196078A (en) 1962-01-30 1965-07-20 Ortho Pharma Corp Process for combating retinits pigmentosa
US3517067A (en) 1964-02-11 1970-06-23 Eastman Kodak Co Syntheses of quaternary phosphonium salts
DE2300107C2 (de) * 1973-01-03 1982-03-11 Basf Ag, 6700 Ludwigshafen Vitamin A-Säureanilid-4-carbonsäureäthylester, Verfahren zu seiner Herstellung und diesen enthaltende Zubereitungen
DE2456959A1 (de) * 1974-12-03 1976-06-16 Basf Ag 4-(e)- und 4-(z)-7-methyl-9-(2,6,6trimethyl-1-cyclohexen-1-yl)-nona-2,4,6,8tetraencarbonsaeure, ihre derivate und diese enthaltende zubereitungen
JPS61275266A (ja) 1985-05-28 1986-12-05 Taisho Pharmaceut Co Ltd レチノイド誘導体
US5310764A (en) 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene
JPH06340525A (ja) * 1993-06-02 1994-12-13 Lion Corp 安定な低眼刺激性ビタミンａ類可溶化点眼剤
NZ283658A (en) 1994-04-04 1999-09-29 William R Freeman Compositions and treatment of increased intraocular pressure with phosphonyl-alkyloxy-pyrimidines/purines (nucleosides)
RU2106843C1 (ru) 1994-06-29 1998-03-20 Красноярская государственная медицинская академия Способ лечения близорукости
JPH08198746A (ja) * 1995-01-18 1996-08-06 Lion Corp 可溶化点眼剤
US5837728A (en) 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
US5489611A (en) 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
EA199700289A1 (ru) * 1995-04-03 1998-04-30 Джонсон энд Джонсон Конзьюмер Продактс, Инк. Композиции для ухода за кожей, содержащие ретиноиды и липосомы
US5620970A (en) * 1995-06-05 1997-04-15 Alcon Laboratories, Inc. Topical ophthalmic carbonic anhydrase inhibitor formulations
US5716627A (en) * 1996-04-25 1998-02-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester
EP0908179A1 (en) * 1997-08-23 1999-04-14 Werner Bollag Treatment of cell-mediated immune diseases
US6391924B1 (en) 1997-12-10 2002-05-21 Hampar Karageozian Taurine derivatives useable in the treatment of ophthalmic disorders
US6552009B2 (en) 1998-07-16 2003-04-22 Gentrix Llc Compositions and methods of treating abnormal cell proliferation
US6372463B1 (en) 1999-05-06 2002-04-16 The President & Fellows Of Harvard College Mutations in nucleic acid molecules encoding 11-CIS retinol dehydrogenase, the mutated proteins, and uses thereof
US6300328B1 (en) 1999-08-06 2001-10-09 Alcon Universal Ltd. Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage
EP1938799B1 (en) 2000-03-10 2013-05-08 Insite Vision Incorporated Compositions for treating and preventing posterior segment ophthalmic disorders and use thereof
US20020028849A1 (en) 2000-04-18 2002-03-07 Godkin James D. Use of retinol in assisted-reproduction protocols
US6696069B2 (en) 2000-06-30 2004-02-24 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Skin care cosmetic compositions containing phosphates and/or sulfates of branched alcohols and/or ethoxylates thereof
CN1455780A (zh) * 2001-01-11 2003-11-12 株式会社开备传 新视黄醇衍生物、其制备方法和用途
CA2435410A1 (en) 2001-01-26 2002-08-01 Steven Baranowitz Systemic formulations containing beta-carotene and derivatives thereof
GB0103998D0 (en) 2001-02-19 2001-04-04 King S College London Method
WO2002082904A2 (en) 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
AU2003210597A1 (en) * 2002-01-18 2003-07-30 Tatton Technologies, Llc. Methods for treating eye disorders
US20030215413A1 (en) 2002-03-22 2003-11-20 L'oreal Compositions containing stabilized retinoid
US20040097587A1 (en) 2002-03-27 2004-05-20 Arbiser Jack L Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
WO2003082081A2 (en) 2002-03-29 2003-10-09 Maxim Pharmaceuticals, Inc. Use of rom production and release inhibitors to treat and prevent intraocular damage
EP3326623A1 (en) 2003-03-14 2018-05-30 University of Washington Retinoid replacements and opsin agonists and methods for the use thereof
US20080176952A1 (en) 2004-02-17 2008-07-24 Rando Robert R Management of Ophthalmologic Disorders, Including Macular Degeneration
US7566808B2 (en) * 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
CA2601278C (en) 2004-03-17 2014-06-10 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
NZ587006A (en) * 2004-06-18 2011-12-22 Univ Washington 11-cis-Retinal derivatives and methods for the use thereof for the treatment of visual disorders
PL1768657T3 (pl) 2004-06-23 2009-01-30 Revision Therapeutics Inc Sposoby i kompozycje do leczenia stanów ocznych za pomocą pochodnych retinylowych
AU2005287343A1 (en) 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
US20080275133A1 (en) 2004-09-30 2008-11-06 University Of Calfornia-San Francisco Local Administration of Retinoids to Treat Deficiencies in Dark Adaptation
WO2009035673A1 (en) 2007-09-12 2009-03-19 Trustees Of Columbia University In The City Of Newyork Compositions and methods for treating macular degeneration
WO2009102418A1 (en) 2008-02-11 2009-08-20 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction

Also Published As

Publication number Publication date
EP2397130A3 (en) 2012-10-31
KR101490145B1 (ko) 2015-02-05
US9174936B2 (en) 2015-11-03
US20130079403A1 (en) 2013-03-28
US20130072559A1 (en) 2013-03-21
US20170014368A1 (en) 2017-01-19
US9388130B2 (en) 2016-07-12
HUE036596T2 (hu) 2018-07-30
US7951841B2 (en) 2011-05-31
CN102976937A (zh) 2013-03-20
EP2397131A3 (en) 2012-10-31
CN1988898A (zh) 2007-06-27
BRPI0511396B1 (pt) 2021-07-27
KR20130079669A (ko) 2013-07-10
NZ552080A (en) 2011-03-31
IN2012DN09335A (2) 2015-08-21
NO339969B1 (no) 2017-02-20
EP1765322A2 (en) 2007-03-28
EP2397130B1 (en) 2019-04-03
MX359668B (es) 2018-10-05
DK2397133T3 (en) 2017-10-30
EP2397132B1 (en) 2017-07-26
CN102976937B (zh) 2016-12-21
US20130072556A1 (en) 2013-03-21
US20080221208A1 (en) 2008-09-11
EP2397133A3 (en) 2012-07-11
IL180078A0 (en) 2007-05-15
CA2571049A1 (en) 2006-01-05
US9403765B2 (en) 2016-08-02
KR20140140616A (ko) 2014-12-09
US10117845B2 (en) 2018-11-06
JP2008503496A (ja) 2008-02-07
CY1114873T1 (el) 2016-12-14
EP2397131B1 (en) 2019-09-11
EP2397131A2 (en) 2011-12-21
EP2397133B1 (en) 2017-07-26
EP1765322B1 (en) 2013-11-06
CA2931917A1 (en) 2006-01-05
PT2397133T (pt) 2017-10-23
BRPI0511396A (pt) 2007-12-04
RS53178B (sr) 2014-06-30
AU2005257997A1 (en) 2006-01-05
SI2397133T1 (sl) 2017-12-29
RU2554003C2 (ru) 2015-06-20
NO20070330L (no) 2007-03-15
KR101337321B1 (ko) 2013-12-06
KR20120062946A (ko) 2012-06-14
EP1765322A4 (en) 2008-09-17
JP5596749B2 (ja) 2014-09-24
EP2397133A2 (en) 2011-12-21
PT1765322E (pt) 2014-02-05
EP2397132A2 (en) 2011-12-21
SI1765322T1 (sl) 2014-03-31
DK1765322T3 (da) 2014-02-10
HK1098696A1 (en) 2007-07-27
NZ587006A (en) 2011-12-22
PL2397133T3 (pl) 2018-01-31
ES2644981T3 (es) 2017-12-01
IL230242A (en) 2015-10-29
HRP20140116T1 (hr) 2014-03-28
RU2408578C2 (ru) 2011-01-10
LT2397133T (lt) 2018-01-10
MXPA06014750A (es) 2007-03-21
ZA200700368B (en) 2008-10-29
KR20070026817A (ko) 2007-03-08
US20130072560A1 (en) 2013-03-21
IL222347A (en) 2017-08-31
WO2006002097A2 (en) 2006-01-05
US9162978B2 (en) 2015-10-20
US20190167626A1 (en) 2019-06-06
JP2012229234A (ja) 2012-11-22
IL230241A (en) 2015-06-30
US9169204B2 (en) 2015-10-27
CY1119480T1 (el) 2018-03-07
CN1988898B (zh) 2012-12-26
US20110288170A1 (en) 2011-11-24
ES2752924T3 (es) 2020-04-06
KR101323122B1 (ko) 2013-10-30
RU2010138410A (ru) 2012-03-27
EP2397132A3 (en) 2012-07-11
AU2005257997B2 (en) 2012-04-05
ES2443194T3 (es) 2014-02-18
JP5166026B2 (ja) 2013-03-21
ES2644984T3 (es) 2017-12-01
EP2397130A2 (en) 2011-12-21
RU2007101735A (ru) 2008-07-27
WO2006002097A3 (en) 2006-05-04
PL1765322T3 (pl) 2014-04-30
CA2571049C (en) 2016-08-09

Similar Documents

Publication Publication Date Title
IL180078A (en) Derivatives of 9-cis retinal for use in treating deficiency of 11-cis retinal
EP1758595A4 (en) Use of lipid conjugates in the treatment of diseases
IL184356A0 (en) Indoles useful in the treatment of inflammation
IL183101A (en) Use of tetrahydrocannabivarin in drug production
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
IL186616A (en) Spyro-oxa-indoles and their use as drugs
IL191057A0 (en) Novel 2-amino-heterocycles useful in the treatment of abeta-related pathologies
EP1912650B8 (en) Use of flibanserin in the treatment of obesity
IL190969A0 (en) Pyrazoles useful in the treatment of inflammation
GB0400700D0 (en) Compounds useful in therapy
SI1885380T1 (sl) Natrijev metaarzenit za uporabo pri zdravljenju metastatičnih neoplastičnih bolezni
IL212214A0 (en) Use of lipid conjugates in the treatment of disease
EP1757282A4 (en) USE OF KAURANE COMPOUNDS IN THE MANUFACTURE OF MEDICAMENTS
SI2340872T1 (sl) Nove farmacevtske formulacije, uporabne v zdravljenju nespečnosti
AU2006251169A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
AU2006251167A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
PL2215908T3 (pl) 2-alkilo-cykloalk(en)ylo-karboksamidy i ich zastosowanie jako fungicydów
PL1933840T3 (pl) Zastosowanie delmopinolu w leczeniu trądziku
GB2411834B (en) Composition for use in the treatment of dry skin conditions
IL185575A0 (en) Benzoxazocines and their therapeutic use
HK1119954A (en) Use of neboglamine in the treatment of toxicodependency
HK1111892A (en) Use of pyrazolyl-pyrimidine derivatives in the treatment of pain
EP1956001A4 (en) PHARMACEUTICAL PRODUCT FOR USE IN THE TREATMENT OF URETEROLITHIASE
IL229982A0 (en) Use of fatty conjugates to treat diseases
IL229981A0 (en) Use of fatty conjugates to treat diseases

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed